PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD
Academic Article
Publication Date:
2020
Short description:
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD / Gilardi, Daniela; Gabbiadini, Roberto; Allocca, Mariangela; Correale, Carmen; Fiorino, Gionata; Furfaro, Federica; Zilli, Alessandra; Peyrin-Biroulet, Laurent; Danese, Silvio. - In: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 1747-4124. - 14:9(2020), pp. 797-806-806. [10.1080/17474124.2020.1785868]
abstract:
Inflammatory bowel diseases (IBDs) are immune-mediated chronic inflammatory disorders of the gastrointestinal tract whose pathogenesis is not yet fully understood. Despite the advent of biological agents, there are still unmet needs for IBD patients, due to suboptimal rate of sustained remission achieved. Small molecule drugs (SMDs), the next generation of selective drugs in IBD, show promising results in ongoing trials.
Iris type:
1.1 Articolo in rivista
Keywords:
Cytochrome P450s; Janus Kinase inhibitors; Small Molecule Drugs; Sphingosine-1-Phosphate Receptor Modulators; drug–drug interactions; inflammatory bowel disease; pharmacodynamics; pharmacokinetics
List of contributors:
Gilardi, Daniela; Gabbiadini, Roberto; Allocca, Mariangela; Correale, Carmen; Fiorino, Gionata; Furfaro, Federica; Zilli, Alessandra; Peyrin-Biroulet, Laurent; Danese, Silvio
Published in: